OptimizeRx
OPRX
113 hedge funds and large institutions have $64.2M invested in OptimizeRx in 2026 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 33 increasing their positions, 42 reducing their positions, and 37 closing their positions.
54% more call options, than puts
Call options by funds: $689K | Put options by funds: $447K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
12% less funds holding
Funds holding: 128 → 113 (-15)
12.8% less ownership
Funds ownership: 72.61% → 59.81% (-13%)
21% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 42
25% less capital invested
Capital invested by funds: $85.8M → $64.2M (-$21.6M)
38% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.12M |
| 2 |
RA
Royce & Associates
New York
|
+$1.16M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$908K |
| 4 |
MBAM
Mink Brook Asset Management
West Palm Beach,
Florida
|
+$812K |
| 5 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$782K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.13M |
| 2 |
State Street
Boston,
Massachusetts
|
-$2.28M |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$2.18M |
| 4 |
Goldman Sachs
New York
|
-$1.46M |
| 5 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
-$1.44M |
OPRX Hedge Fund Activity: Q2 2026 in Review
113 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in OptimizeRx (OPRX) for Q2 2026, worth a combined $64.2M — down 25% from $85.8M a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of OPRX and 23 opened new positions — a net loss of 14 holders — while 42 trimmed existing stakes and 33 added.
The largest buyer was AQR Capital Management, adding an estimated $2.12M. The largest seller was BlackRock, cutting an estimated $4.13M.
- 113 institutional investors held OptimizeRx (OPRX) as of Q2 2026, down from 128 in Q1 2026.
- Funds reported $64.2M of OptimizeRx stock for Q2 2026, down 25% quarter-over-quarter.
- 23 funds opened new OptimizeRx positions in Q2 2026 and 37 closed out, a net change of -14 holders.
- The largest OptimizeRx buyer in Q2 2026 was AQR Capital Management, an estimated $2.12M added.
- The largest OptimizeRx seller in Q2 2026 was BlackRock, an estimated $4.13M sold.
Based on aggregated 13F filings for Q2 2026.